Appointment dossier — Ovarian Epithelial Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Ovarian Epithelial Carcinoma
- Bevacizumab — Human evidence · 1 positive · PMID 35720032, 39013199
- Olaparib — Human evidence · 1 positive · PMID 35720032, 39013199
- Relacorilant — Human evidence · 0 positive / 1 negative-mixed · PMID 37364223
- Anastrozole — Review evidence · 0 positive · PMID 39013199
- Carboplatin — Review evidence · 0 positive · PMID 39013199
- Cisplatin — Review evidence · 0 positive · PMID 39013199
- Docetaxel — Review evidence · 0 positive · PMID 39013199
- Gemcitabine — Review evidence · 0 positive · PMID 39013199
- Liposomal Doxorubicin — Review evidence · 0 positive · PMID 39013199
- Niraparib †Rx — Review evidence · 0 positive · PMID 39013199
- Paclitaxel — Review evidence · 0 positive · PMID 39013199
- Rucaparib — Review evidence · 0 positive · PMID 39013199
- Tamoxifen — Review evidence · 0 positive · PMID 39013199
- Topotecan — Review evidence · 0 positive · PMID 39013199
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07109726 · Phase 1 / Phase 2 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations (United States)
- NCT07488676 · Phase 1 / Phase 2 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors (United States)
- NCT07807956 · Phase 1 — A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors (United States)
- NCT05518253 · Phase 1 — A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors (China)
- NCT06547840 · Phase 1 — A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha (United Kingdom)
- NCT07715747 · Phase 1 — A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors (China)
- NCT05427487 · Phase 1 — Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (Australia)
- NCT07334119 · Phase 1 — Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors (Australia)
- NCT05255471 · Phase 3 — MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (Italy)
- NCT07340164 · Phase 2 — Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy (South Korea)
- NCT06580002 · Phase 2 — Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial (United States)
- NCT07736937 · Phase 1 / Phase 2 — Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer (United States)
- NCT07617753 · Phase 1 / Phase 2 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 (China)
- NCT07158021 · Phase 2 — Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial (United States)
- NCT07665515 · Phase 1 — Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (United Kingdom)
- NCT07318051 — Sample Collection for Ongoing Research and Product Evaluation Study (United States)
- NCT07039331 — Short-term Fasting Compared to Free Diet on Ovarian Cancer Patients (Italy)
- NCT06129968 — Transforming Ovarian Cancer Diagnostic Pathways (United Kingdom)
Most-relevant first: trials that name Ovarian Epithelial Carcinoma, then broader trials you may still qualify for. 631 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Niraparib †Rx × CYP1A2 inhibitors (high-stakes) — Monitor (low)
- Niraparib †Rx × P-gp substrates (high-stakes) — Monitor (low)
- Niraparib †Rx × Bevacizumab — Synergize (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Bevacizumab has been studied in people for Ovarian Epithelial Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Olaparib has been studied in people for Ovarian Epithelial Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Relacorilant has been studied in people for Ovarian Epithelial Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT07109726), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?